UroGen Pharma第三季度每股收益$（0.69），内联，销售额27500万美元，低于3309.3万美元的预期

UroGen Pharma (NASDAQ: URGN) reported quarterly losses of $(0.69) per share which met the analyst consensus estimate. This is a 25.45 percent decrease over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $27.500 million which missed the analyst consensus estimate of $33.093 million by 16.90 percent. This is a 9.11 percent increase over sales of $25.204 million the same period last year.